Pertussis in early infancy: Disease burden and preventive strategies

Current Opinion in Infectious Diseases

Volumn 22, Issue 3, 2009, Pages 215-223

  McIntyre, Peter ^a,b,c   Wood, Nicholas ^a,b,c  

^a NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Epidemiology; Infant; Pertussis; Prevention; Vaccine

Indexed keywords

MATERNAL ANTIBODY; PERTUSSIS VACCINE;

CLINICAL TRIAL; EPIDEMIC; HAEMOPHILUS INFLUENZAE TYPE B; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFANT DISEASE; PASSIVE IMMUNIZATION; PERTUSSIS; PRENATAL CARE; PREVENTIVE HEALTH SERVICE; REVIEW; VACCINATION; INFANT; METHODOLOGY; NEWBORN;

HUMANS; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; VACCINATION; WHOOPING COUGH;

EID: 65549166748     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32832b3540     Document Type: Review

References (78)

1. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis 2003; 3:413-418.
2. World Health Organization. Global burden of disease estimates 2002. 2002; Geneva: World Health Organization; 2008.
3. Crowcroft NS, Andrews N, Rooney C, et al. Deaths from pertussis are underestimated in England. Arch Dis Child 2002; 86:336-338.
4. Elliott E, McIntyre P, Ridley G, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004; 23:246-252.
5. Hallander HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999; 28:S99-S106.
6. Juretzko P, Fabian-Marx T, Haastert B, et al. Pertussis in Germany: regional differences in management and vaccination status of hospitalized cases. Epidemiol Infect 2001; 127:63-71.
7. Lievano FA, Reynolds MA, Waring AL, et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 2002; 40:2801-2805.
8. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238-242.
9. Wendelboe AM, Njamkepo E, Bourillon A, et al., Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-299. This is a multicentre study of 95 laboratory-confirmed pertussis cases and 404 contacts and describes detailed clinical and demographic data on cases and contacts. Household members were responsible for most transmission in cases where a source was identified.
10. Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006; 333:174-177.
11. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr 2008; 167:133-139. A recent review article that includes potential vaccination strategies as well as additional information on pertussis epidemiology and laboratory diagnosis.
12. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38:800-806.
13. Poynten IM, Hanlon M, Irwig L, Gilbert GL. Serological diagnosis of pertussis: evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection. Epidemiol Infect 2002; 128:161-167.
14. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998; 17:412-418.
15. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the USA, 1980-1999. JAMA 2003; 290:2968-2975.
16. Murphy TV, Slade BA, Broder KR, et al., Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2008; 57:1-51. A detailed review of pertussis epidemiology, clinical features, diagnosis, antibiotic prophylaxis and DTPa vaccine safety and efficacy. This article presents the CDC Advisory Committee on Immunization practice recommendations for preventing pertussis in pregnant women and infants.
17. Cortese MM, Baughman AL, Zhang R, et al. Pertussis hospitalizations among infants in the USA, 1993 to 2004. Pediatrics 2008; 121:484-492. A recent large study measuring pertussis hospitalizations, using two national inpatient discharge databases and a national surveillance system, in the USA over an 11-year period. Provides detailed information on the comorbidity associated with infant pertussis. Hospitalization rates were two times higher than estimates from passive systems.
18. Murphy TV, Syed SB, Holman RC, et al. Pertussis-associated hospitalizations in American Indian and Alaska Native infants. J Pediatr 2008; 152:839-843.
19. Kolos V, Menzies R, McIntyre P. Higher pertussis hospitalization rates in indigenous Australian infants, and delayed vaccination. Vaccine 2007; 25:588-590.
20. Moraga F, Roca J, Mendez C, et al., TOSCA Study Group. Epidemiology and surveillance of pertussis among infants in Catalonia, Spain, during 1997-2001. Pediatr Infect Dis J 2005; 24:510-513.
21. Hviid A, Stellfeld M, Andersen PH, et al. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 2004; 22:3530-3534.
22. Galanis E, King AS, Varughese P, Halperin SA. IMPACT i: Changing epidemiology and emerging risk groups for pertussis. CMAJ 2006; 174:451-452.
23. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003; 22:22-27.
24. Bettinger JA, Halperin SA, De Serres G, et al. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007; 26:31-35.
25. Brotherton J, McIntyre P, Puech M, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002. Commun Dis Intell 2004; 28 (Suppl 2):i-S116.
26. Van Buynder PG, Owen D, Vurdien JE, et al. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect 1999; 123:403-411.
27. Rendi-Wagner P, Kundi M, Mikolasek A, et al. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006; 24:5960-5965.
28. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008; 9:201-212.
29. Wood N, McIntyre P, Elliott E. Pertussis in infancy: a review of strategies for prevention. Sociedad Iberoamericana de Informacion Cientifica (SIIC) online, 29 May 2007. http://www.siicsalud.com/dato/dat052/ 07528000.htm
30. Wood N, Quinn HE, McIntyre P, Elliott E. Pertussis in infants: preventing deaths and hospitalisations in the very young. J Paediatr Child Health 2008; 44:161-165.
31. Fisman D, Tang P, Brett V. Laboratory factors in an apparent pertussis resurgence [abstract]; Toronto, Canada; 2005-2007. 47th Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy. 2007. Chicago, USA. 2007.
32. Heininger U, Cherry JD. Pertussis immunisation in adolescents and adults: Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther 2006; 6:685-697.
33. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24 (5suppl):S10-S18.
34. Godfroid F, Denoel P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev Vaccines 2005; 4:757-778.
35. Briand V, Bonmarin I, Lévy-Bruhl D. Study of the risk factors for severe childhood pertussis based on hospital surveillance data. Vaccine 2007; 25:7224-7232.
36. Namachivayam P, Shimizu K, Butt W. Pertussis: severe clinical presentation in pediatric intensive care and its relation to outcome. Pediatr Crit Care Med 2007; 8:207-211. A description of the clinical features and management of 20 years of pertussis cases admitted to a paediatric ICU in Australia.
37. Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328-338. An important article that examines pulmonary histopathology in postmortem samples of 15 infants who died from pertussis and describes in detail the pathology and pathogenesis of fatal infections. A novel immunohistochemical stain was used to document the distribution of B. pertussis in lung tissue.
38. Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative round-table meeting. Vaccine 2007; 25:2634-2642.
39. Olin P, Gustafsson L, Barreto L, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21:2015-2021.
40. Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33:1004-1010.
41. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 2003; 22:956-959.
42. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the USA in the 1990s. Pediatr Infect Dis J 2003; 22:628-634.
43. Somerville RL, Grant CC, Scragg RK, Thomas MG. Hospitalisations due to pertussis in New Zealand in the preimmunisation and mass immunisation eras. J Paediatr Child Health 2007; 43:147-153. This article examines hospitalization discharge data from 1873 and notes the decrease in rates following the introduction of mass pertussis immunization in 1960; however, rates have increased since 1971 and are most likely due to poor vaccine coverage and sociodemographic factors, such as poverty and overcrowding.
44. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 2008; 27:218-223. This article examined hospitalizations and notifications in the Netherlands before and after introduction of a preschool booster at 4-6 years. This is the only article showing reduced rates in infants due to a possible herd effect, reduced transmission from siblings to young infants, from the preschool booster.
45. Hviid A, Stellfeld M, Wohlfahrt J, et al. The impact of preschool booster vaccination of 4-6-year-old children on pertussis in 0-1 year-old children. Vaccine 2006; 24:1401-1407.
46. Kandola K, Lea A, White W, Santos M. A comparison of pertussis rates in the Northwest Territories: pre and post acellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol 2005; 16:271-274.
47. Baptista PN, Magalhaes V, Rodrigues LC, et al. Source of infection in household transmission of culture-confirmed pertussis in Brazil. Pediatr Infect Dis J 2005; 24:1027-1028.
48. Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005; 24:S19-S24.
49. Ward JI, Cherry JD, Chang SJ, et al., APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555-1563.
50. de La Rocque F, Grimprel E, Gaudelus J, et al. Vaccination in parents of young infants survey. Arch Pediatr 2007; 14:1472-1476.
51. National Health and Medical Research Council. The Australian Immunisation Handbook. 9th ed. Canberra: Australian Government, Department of Health and Ageing; 2008.
52. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22:3154-3165.
53. Coudeville L, Van Rie A, Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the USA: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008; 136:604-620. This modelling article comprehensively reviews the impact of six different vaccine strategies, childhood, adolescent, cocoon, cocoon and single adult dose and routine adult, using US epidemiology data, for preventing pertussis.
54. Dylag AM, Shah SI. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 2008; 122:e550-e555.
55. Calugar A, Ortega-Sanchez IR, Tiwari T, et al. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating healthcare workers. Clin Infect Dis 2006; 42:981-988.
56. Peadon E, Cooper C. Whooping cough: are health-care workers putting children at risk? J Paediatr Child Health 2007; 43:398-402.
57. Barreto L, Guasparini R, Meekison W, et al. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007; 25:8172-8179.
58. Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007; 44:1271-1277.
59. Bailleux F, Coudeville L, Kolenc-Saban A, et al. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008; 26:3903-3908. Long-term (5 years) follow-up of serological immunity after DTPa vaccination in a cohort enrolled in a clinical trial was reported. Observed data were used to mathematically model predicted rates of antibody decay. This article suggests that sero-immunity wanes at 10 years and may require booster doses at this time point.
60. World Health Organization. WHO Immunization Schedule. World Health Organization Immunization Policy: Global Programme for Vaccines and Immunization-Expanded Programme on Immunization. WHOGPV/GEN/95.03 Rev.1. 1996; Geneva: World Health Organization; 2008.
61. Shinall MC Jr, Peters TR, Zhu Y, et al. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics 2008; 122:1021-1026. This article models the impact of giving the first dose of DTPa vaccine at 6 weeks instead of 2-months-old in the USA. Results suggest a reduction in hospitalizations and deaths in under 3-month-olds of 6-9%.
62. Grant CC, Roberts M, Scragg R, et al. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. BMJ 2003; 326:852-853.
63. Hull BP, McIntyre PB. Timeliness of childhood immunisation in Australia. Vaccine 2006; 24:4403-4408.
64. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007; 7:614-624. This article is an excellent review of maternal vaccination against pertussis and reports on animal and human studies, as well as potential difficulties with this vaccine strategy.
65. Dalhousie University C. Pertussis maternal immunization study. Dalhousie University: Canada; 2008.
66. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005; 192:1098-1106.
67. Healy CM, Baker CJ. Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis 2006; 19:271-276.
68. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96:580-584.
69. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190:335-340.
70. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005, 24 (5 Suppl):S62-S65.
71. Edwards KM. Pertussis: an important target for maternal immunization. Vaccine 2003; 21:3483-3486.
72. Baraff LJ, Leake RD, Burstyn DG, et al. Immunologic response to early and routine DTP immunization in infants. Pediatrics 1984; 73:37-42.
73. Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant I: pertussis inoculation within twenty-four hours of birth. N Engl J Med 1965; 273:959-965.
74. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111: 1042-1045.
75. Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153: 327-332. This US study is the first report on the immunogenicity of DTPa vaccine administered at birth and details pertussis and concomitant antigen responses after completion of the primary vaccine series. Reduced responses are seen in the intervention group compared with controls suggesting possible immune tolerance.
76. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655-660. This article is the second one to report on the immunogenicity of acellular pertussis vaccine at birth. Pertussis antibody responses are higher following birth vaccination compared with controls; however, reduced Hib responses were seen.
77. *].
78. Saffar MJ, Ajami A, Khalilian AR, et al. Pertussis seroimmunity among mother-infant pairs and infant immune response to pertussis vaccination. Indian Pediatr 2007; 44:916-918.